| INTRODUCTION
Allergic airway diseases are thought to be caused by aberrant immune responses against inhaled airborne allergens. 1 Exposed to the outside environment, the lung epithelium not only serves as a barrier against pathogens and environmental insults but also plays an important role in airway immune responses. Indeed, upon exposure to inhaled airborne allergens, lung epithelial cells secrete inflammatory cytokines that activate immune cells involved in type 2 immunity. 2 Among various products of epithelial cells, three epithelium-derived cytokines, interleukin (IL)-33, IL-25, and thymic stromal lymphopoietin (TSLP), have been identified as having critical functions in the pathophysiology of allergic airway diseases. 3, 4 IL-33 was first identified in 1999 as the protein DVS27 expressed in canine arteries, 5 and later in 2003 as "nuclear factor from high endothelial venules" (NF-HEV) expressed in human endothelial cells. 6 IL-33 was rediscovered in 2005 by a computational sequence search, which identified it as an IL-1 family member. At the time, IL-33 was given the official name "IL-33". 7 Conversely, IL-33 receptor, designated IL-1-receptor-like 1 (IL1RL1) and commonly known as suppression of tumorigenicity 2 (ST2), was first reported in 1989 as a serum-responsive protein in murine fibroblasts that shared sequence homology with the IL-1 receptor. 8 [18] [19] [20] macrophages, 21 eosinophils, 22 DCs, 23 basophils, natural killer (NK) T cells, and NK cells. 24, 25 Through binding to the ST2, IL-33 activates target cells to produce and secrete cytokines and growth factors that promote and/or regulate local and systemic immunity.
Since the discovery of IL-33, tremendous progress has been made in understanding its biological functions. Studies have shown that IL-33 is a multifunctional cytokine that plays critical roles in a variety of
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biological responses, such as the development and regulation of immune responses, maintenance of tissue homeostasis, repair, and remodeling.
Evidence suggests that IL-33 is likely involved in pathogenesis of various human diseases. Outstanding reviews have been published recently to describe the biology of IL-33 and its roles in diseases in general, [26] [27] [28] and readers are asked to refer to them for comprehensive information. The potential importance of IL-33 in allergic airway diseases in humans has been supported by multiple genome-wide association studies (GWAS), which have shown that IL-33 and its receptor ST2 are associated with asthma susceptibility. [29] [30] [31] [32] [33] Animal models have shown that the IL-33/ ST2 pathway plays a critical role in allergen-induced innate and adaptive immune responses and inflammation in the airway. [34] [35] [36] [37] [38] In this article,
we have focused on the roles of IL-33 in airway mucosa and have cited the evidence for the involvement of IL-33 in allergic airway diseases.
| MOLECULAR FEATURES OF IL-33
The human and mouse IL-33 genes are located on chromosome Human and mouse full-length IL-33 proteins are 270 and 266 amino acids long, respectively, and the two proteins are 55% homologous. 7 The IL-33 protein can be divided into three functional domains; nuclear domain, central domain, and IL-1-like cytokine domain 43 ( Figure 1A ). The nuclear domain (amino acids 1-65 in humans) is encoded by exons 2-3 and contains a chromatin-binding motif (amino acids [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] . 44 Under basal conditions, the chromatin-binding motif localizes IL-33 protein to the nucleus and tethers IL-33 to chromatin by interacting with the histone H2A-H2B dimer. 44 The central domain (amino acids 66-111 in humans) of IL-33 is encoded by exon 4 and contains protease cleavage sites, which are sensitive to neutrophiland mast cell-derived proteases. 45, 46 The IL-1-like cytokine domain (amino acids 112-270 in humans) of IL-33 is encoded by exons 5-8, binds to ST2 on target cells, and mediates the cytokine activities. 7, 47 While full-length approximately 31 kDa IL-33 has cytokine activities, 48 processing of IL-33 by cleavage at the central domain and removal of the N-terminal peptides increased its activity by approximately 30-fold. 45, 46 Exogenous proteases that are derived from inflammatory cells, such as neutrophil cathepsin G, neutrophil elastase, and mast cell serine proteases, are capable of processing IL-33 45, 46 ( Figure 1 ), while it is still unknown whether and which endogenous protease(s) have a similar capacity. In addition, caspases that are active during cellular apoptosis, such as caspase 3, caspase 7, and likely caspase 1, regulate IL-33 activity. Indeed, the IL-33 protein contains a consensus caspase cleavage site in its cytokine domain (Figure 1 ). In contrast to the neutrophil-and mast cell-derived proteases, caspases inactivate IL-33 by cleaving it into biologically inactive fragments.
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| EXPRESSION OF IL-33
Under basal conditions, IL33 mRNA and protein are constitutively and abundantly expressed in many tissues in mice and humans. 6, 7, 9 Therefore, IL-33 has been considered as an "alarmin" cytokine that is stored and released quickly in response to cellular damage or tissue injury. 9 Specifically in the airway, bronchial epithelial cells and endothe- 
| PROCESSING AND RELEASE OF IL-33
The cytokine activity of IL-33 is regulated by its cellular location and 55 ; ATP has been considered a classical DAMP that is released by stressed cells. 4 Finally, the application of biomechanical strain to human fibroblasts induced IL-33 secretion in the absence of cellular necrosis. 68 The signaling pathway that mediates active IL-33 secretion is currently unknown, although several key factors have been identified. IL-33
release from NHBE cells that are exposed to fungal allergens involved acute extracellular accumulation of ATP, autocrine and paracrine activation of P2 purinergic receptors, and subsequent increase in intracellular Ca 2+ concentrations. 65 The administration of Ca 2+ chelators, cellular treatment with P2 purinergic receptor antagonists, or genetic knockdown of these receptors inhibited Alternaria-induced IL-33 release.
Likewise, the inhibition of P2 purinergic receptors reduced Alternariainduced IL-33 release as reported in other studies. 35, 67 In addition, in airway epithelial cells exposed to Alternaria or house dust mite (HDM) extracts, NADPH oxidase dual oxidase 1 (DUOX1) has been shown to be activated as a result of the engagement of P2 purinergic receptors and mediated IL-33 secretion. 67 Nucleotide-binding domain leucine- range on SDS-PAGE gels, respectively. 70 The expression of both forms of IL-33 was upregulated by intranasal administration of chitin, a component of common airborne allergens. 70 Similarly, the expression of both the full-length and processed forms of IL-33 was upregulated in the mouse lung during chronic airway inflammation. 71 Upon Alternaria exposure in mice, IL-33 was released into the bronchoalveolar la- 
| BIOLOGICAL FUNCTIONS OF IL-33
In principle, IL-33 can work intracellularly as a transcription regulator or extracellularly as a cytokine. Although IL-33 is expressed constitutively and the protein is localized in the nucleus, its nuclear function is not well understood. IL-33 has been shown to regulate chromatin compaction 44 and NF-κB transcriptional activity in transfected cells. 73 However, when nuclear IL-33 was knocked down in primary human endothelial cells, these cells displayed unaltered proteomes and NFkB expression as compared to that of the wildtype cells, suggesting that endogenous nuclear IL-33 does not play a significant role in gene transcription. 74 Furthermore, the mice lacking IL-33 gene were fertile and did not appear to show gross abnormalities at the resting condition.
The functions of extracellular IL-33 as a cytokine have been extensively studied (Figure 2 Thus, IL-33 may promote or regulate CD4 + T cell-mediated immune responses depending on their conditions and/or tissue environment.
| IL-33 IN ADAPTIVE IMMUNITY
Future studies will be necessary to elucidate the mechanisms of how IL-33 dictates the direction of these immune responses.
| IL-33 AND CHRONIC AIRWAY INFLAMMATION
Human asthma is generally characterized by chronic airway inflammation, airway hyper-reactivity, and tissue remodeling. 113 While IL-33 is likely involved in the initiation of innate and adaptive type 2 immunity, emerging data also suggest that IL-33 plays an important role in chronic and persistent airway inflammation. Allergic patients with asthma are often sensitized to multiple allergens. 114 To mimic this, mouse models have been developed in which mice are exposed to the extracts of several airborne allergens, such as Alternaria, HDM, ragweed, and
Aspergillus, for a prolonged period of up to 12 weeks. 36, 71 In these models, IL-33 expression in the lung was dramatically increased during the chronic phase of allergen exposure, and was accompanied by increased numbers of CD4 + T cells and ILC2s in the lung. ST2-deficient mice or the administration of anti-IL-33 antibody caused attenuated allergen-induced immune responses in these "chronic" models, 36, 71 suggesting that increased IL-33 expression in the lung may play a key role in maintaining the chronic airway response. Furthermore, in these models, ILC2-derived IL-13 appeared to play roles in the upregulation of IL-33 in airway epithelium. 71 Importantly, a separate study showed 
| IL-33 IN HUMAN AIRWAY DISEASES
As described above, the use of animal models and in vitro studies have suggested that IL-33 may play a key role in immunity, inflammation, and homeostasis of mucosal tissues. IL-33 may be important for allergic airway diseases in humans. Indeed, the IL33 and ST2/IL1RL1 genes were found to be associated with asthma and allergic rhinitis in several GWAS studies that included thousands of human subjects from diverse ethnic groups. [29] [30] [31] [32] [33] 127 Below, we have discussed the studies that investigated the potential roles of IL-33 and ILC2s in human airway diseases, including asthma, allergic rhinitis, and CRS.
| Asthma
Examinations of airway specimens from patients with asthma showed increased IL-33 mRNA expression in cells from induced sputum 128 and in airway epithelial cells from bronchial biopsy specimens. 49 Interestingly, the expression of an IL33 spliced variant lacking exons 3 and 4 was strongly associated with airway type 2 inflammation in patients with asthma. 42 As discussed above, exon 3 and exon 4 encode the nuclear localization domain and central domain, respec- Since the discovery of ILC2s in mice, ILC2s have been identified in peripheral blood and mucosal tissues of humans. 131 The numbers of IL-33-responsive ILC2s were increased in peripheral blood and BAL fluids in subjects with allergic asthma as compared to those of healthy control subjects or those with allergic rhinitis. 71, 132, 133 Moreover, the ILC2s from patients with asthma appeared to be more sensitive to IL-33 when compared to those from control subjects. 132 The number of ILC2s in blood was associated with the magnitudes of tissue eosinophilia 134 and clinically unstable asthma. 133 Furthermore, IL-33 and type 2 cytokines were induced during a rhinovirus-induced asthma exacerbation, 135 suggesting that virus-induced IL-33 and IL- While peripheral blood ILC2 numbers in allergic rhinitis were not different from those of control subjects under stable conditions (eg, out of allergy season), 132 airway allergen exposure in patients with allergic rhinitis increased the numbers of blood ILC2s. 137 Blood ILC2 numbers also were significantly increased in patients with seasonal allergic rhinitis during grass pollen season. 138 Interestingly, ILC2s were increased in allergic rhinitis patients who were sensitive to HDM, but not to those sensitive to mug wort, 139 suggesting that the biochemical nature of the allergens may have affected the levels of ILC2s and perhaps of IL-33. Thus, within the patients who showed clinical symptoms of allergic rhinitis, some heterogeneity existed in the immunopathogenesis of the disease.
| Chronic rhinosinusitis
CRS is one of the most common chronic diseases in adults in the United States, and it produces significant morbidity and cost to the health care system. 140 CRS represents >12 weeks of chronic inflammation in paranasal sinuses, and can be divided into two subtypes, CRS without nasal polyps (CRSsNP) and CRS with nasal polyps (CRSwNP). 141 CRSsNP and CRSwNP show distinct inflammatory endotypes with CRSwNP being associated with increased levels of tissue IL-5, tissue eosinophilia, and concomitant asthma. 142 IL-33 was upregulated in nasal polyp tissues from patients with CRSwNP as compared with those of CRSsNP or healthy control subjects. [143] [144] [145] [146] Furthermore, IL-33 mRNA expression in nasal biopsy specimens was higher in CRSwNP patients, in particular those who were resistant to treatment. 147 Similarly, ILC2 numbers in sinus mucosal biopsies were increased in patients with CRSwNP and were associated with tissue and blood eosinophilia. 131, [148] [149] [150] The levels of ILC2s correlated with the severity of nasal symptoms 148 and were reduced following systemic corticosteroid treatment. 150 Furthermore, IL-33-responsive and highly pathological memory CD4 + T cells were enriched in nasal polyp tissues from patients with eosinophilic CRS. 115 
| CONCLUSIONS AND PERSPECTIVES
As summarized in Figure 2 , there is accumulating evidence to suggest that IL-33 plays important roles in innate and adaptive immunity in mucosal organs as well as in the homeostasis and repair of the airway. will be gained in the coming years to answer many of these questions.
